ArticlePharmaceutical nanotechnology2026
Formulation and Assessment of an Optimized Glimepiride Transdermal Therapeutic System Using 3
Article in Pharmaceutical nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrently, a large number of populations are suffering from diabetes mellitus, which significantly increases the burden on public health. Glimepiride is an antidiabetic drug with a shorter half-life (approximately 5 hours), low bioavailability, and first-pass metabolism. Due to these limitations, it is required to maintain a uniform therapeutic level, and it has been chosen as a transdermal drug delivery approach.
objectivesThe main objective of this investigation was to evaluate glimepiride-loaded transdermal patches on the skin to treat diabetes mellitus. To overcome the issue of oral glimepiride and provide a localized effect, a transdermal drug delivery approach was developed.
methodsThe glimepiride transdermal drug delivery approach was developed by using the solvent evaporation method. To examine the impact of altering amounts of polyvinyl alcohol (X RESULTS AND DISCUSSION: The formulation F4 with 1300.00 milligrams of polyvinyl alcohol and 600.00 milligrams of polyvinyl pyrrolidone demonstrated a release of 96.17% for up to 24 hours and zero order release kinetics consisting of r
conclusionThe findings of this research work were demonstrated the potential of the 3
Indexed as
Identifiers
39660519What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.